MapLight Therapeutics, Inc. (MPLT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.77+4.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MPLT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on advancing ML-007C-MA for schizophrenia with registrational Phase 3 ZEPHYR-2 trial following positive Phase 2 results and FDA End-of-Phase 2 engagement.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. The Phase 2 ZEPHYR trial met its primary endpoint with a statistically significant reduction in PANSS total score (p=0.015), supporting advancement to the planned registrational Phase 3 ZEPHYR-2 trial. Management has consistently emphasized FDA End-of-Phase 2 engagement and trial planning, indicating delivery on this strategic clinical development priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“ZEPHYR met its primary endpoint supporting planned registrational Phase 3 ZEPHYR-2 trial; plan to engage FDA at End-of-Phase 2 meeting.”
“Completed enrollment in Phase 2 ZEPHYR trial with topline results expected by mid-August 2026; planning Phase 3 ZEPHYR-2 trial.”
Continue enrollment and development of ML-007C-MA in Phase 2 VISTA trial for ADP with topline results expected in second half of 2027.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. Management reports ongoing enrollment in the Phase 2 VISTA trial for ADP with topline results expected in the second half of 2027 and FDA Fast Track designation granted in December 2025. The trajectory shows consistent advancement of this clinical program aligned with management’s stated development timeline.
“Enrollment ongoing in Phase 2 VISTA trial for ADP; topline results expected in second half of 2027; FDA Fast Track designation received.”
“Enrollment ongoing in Phase 2 VISTA trial for ADP; topline results expected in second half of 2027.”
Evaluate ML-004 following Phase 2 IRIS trial showing clinically meaningful improvements in irritability in adolescents with ASD; plan FDA End-of-Phase 2 meeting to determine path forward.
Newly stated in 2026-Q2 and related disclosures. The Phase 2 IRIS trial of ML-004 demonstrated clinically meaningful improvements in irritability in adolescents with ASD. Management plans to engage the FDA in an End-of-Phase 2 meeting to determine the development path. This priority is emerging with initial clinical data supporting further evaluation.
Preserve financial strength with cash, cash equivalents, and investments sufficient to fund operations through 2028, supported by $150 million private placement in August 2026.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. Cash and investments declined from $395.2M in 2026-Q1 to $351.3M in 2026-Q2, reflecting operational use, but a $150M private placement in August 2026 is expected to extend runway through 2028. Management is delivering on maintaining financial strength to support clinical programs.
“Ended quarter with $351.3 million in cash; recent $150 million private placement expected to extend runway through 2028.”
“Ended quarter with $395.2 million in cash, expected to fund operations through 2027.”
“Strong financial position with ~$450 million in cash and runway through 2027.”
Control operating expenses and cash burn amid increased R&D and G&A spending to support clinical development programs.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. Net loss doubled from $29.8M in 2025-Q2 to $60.2M in 2026-Q2, driven by increased R&D expenses rising from $26.8M to $53.4M and G&A expenses from $3.8M to $10.1M. Management continues to invest heavily in clinical development, reflecting limited progress in reducing operating losses but consistent with stated priorities.
“Net loss was $60.2 million; R&D expenses $53.4 million; G&A expenses $10.1 million.”
“Net loss was $60.7 million; R&D expenses $53.7 million; G&A expenses $10.8 million.”
“Net loss was $29.8 million; R&D expenses $26.8 million; G&A expenses $3.8 million.”
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.